Effect of intracameral administration of carbachol on the postoperative increase in intraocular pressure in dogs undergoing cataract extraction.
OBJECTIVE
To determine whether intracameral injection of carbachol at the completion of phacoemulsification in dogs would prevent the increase in intraocular pressure (i.o.p) that can develop during the first 24 hours after surgery.


METHODS
Randomized controlled trial.


METHODS
32 adult dogs undergoing elective unilateral or bilateral phacoemulsification.


METHODS
Dogs were randomly assigned to 1 of 4 groups with 8 dogs/group: phacoemulsification and intracameral administration of 0.5 ml of 0.01% carbachol at the end of surgery; phacoemulsification, intraocular lens implantation, and intracameral administration of 0.5 ml of 0.01% carbachol; phacoemulsification and intracameral administration of 0.5 ml of balanced salt solution; and phacoemulsification, intraocular lens implantation, and intracameral administration of 0.5 ml of balanced salt solution. Intraocular pressure was measured at 3 and 6 hours and the morning after surgery. Aqueous flare was also measured 6 hours and the morning after surgery.


RESULTS
None of the dogs treated with carbachol developed postoperative ocular hypertension (i.e., IOP > 27 mm of Hg), whereas 12 of 16 control dogs had ocular hypertension 3 hours after surgery. Intraocular pressure 3 hours after surgery was not significantly associated with phacoemulsification time or phacoemulsification power or with whether the dog received an intraocular lens implant. Severity of aqueous flare was similar for treated and control dogs.


CONCLUSIONS
Results suggested that intracameral administration of 0.01% carbachol at the end of surgery was a safe and efficacious method of preventing the postoperative increase in IOP associated with phacoemulsification in dogs.
Stuhr
C M
CM
Department of Surgical (Stuhr, Miller, Murphy, Schoster) Science, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1102, USA.
Miller
P E
PE
Murphy
C J
CJ
Schoster
J V
JV
Thomas
C B
CB
D000818:Animals; D000867:Anterior Chamber; D002217:Carbachol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004283:Dog Diseases / Q000209:etiology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D007267:Injections / Q000662:veterinary; D007429:Intraocular Pressure / Q000187:drug effects; D007910:Lenses, Intraocular / Q000662:veterinary; D008297:Male; D008916:Miotics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009798:Ocular Hypertension / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*; D010277:Parasympathomimetics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018918:Phacoemulsification / Q000009:adverse effects / Q000662:veterinary*; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control / Q000662:veterinary*
D008916:Miotics; D010277:Parasympathomimetics; D002217:Carbachol